Qureight Welcomes New Chief Operating Officer
Qureight Ltd has appointed Rebecca Simmons as chief operating officer. The techbio company develops AI tools that extract CT imaging biomarkers and manage clinical data for lung and heart disease research. In her new role Simmons will lead global business operations and support product and commercial scaling across clinical trials and research partnerships.
A Proven Track Record in Deep Tech and Funding
Simmons joins Qureight from Riverlane, where she led growth and operations and played a central role in securing venture capital and government grants. Her experience includes building teams for deep tech startups, managing investor relations, and driving collaborations with the NHS and academic partners. That blend of fundraising know how and operational execution positions her to accelerate Qureight’s transition from R D to broader market deployment.
Scaling AI-Powered Solutions for Clinical Impact
Qureight’s platform combines AI-driven CT imaging biomarkers with a clinical data management layer designed for trials and observational studies. Simmons’ mandate will include expanding partnerships with pharma, contract research organisations, and academic networks to validate imaging endpoints in lung and cardiovascular disease. Her arrival signals a push to generate regulatory grade evidence, streamline data workflows, and scale deployments that support drug development and real world research.
Strategic Leadership for AI in Health
This appointment underlines a broader trend in AI biotech: teams are adding operational leaders with deep tech and funding experience to bridge research innovation and commercial adoption. For investors and partners, Simmons’ track record reduces execution risk and strengthens Qureight’s capacity to deliver reproducible imaging biomarkers at scale. Watch for updates on new trial partnerships, regulatory milestones, and commercial agreements as she implements the companys growth strategy.
Stay informed: Subscribe to HealthAIInsiders for analysis of leadership moves, funding signals, and the impact of AI on medical imaging and drug development.
